NON-INFECTIOUS ACUTE TOXICITIES IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING INTENSIVE CHEMOTHERAPY: EVALUATION WITH STANDARDIZED CRITERIA


Gündüz M., Tüfekçi Gürocak Ö., Okur Acar S., Yurdusev T., Kurdu Ç. B., Yılmaz Ş., ...Daha Fazla

58th Congress of the International Society of Paediatric Oncology (SIOP), Texas, Amerika Birleşik Devletleri, 15 - 18 Eylül 2026, cilt.1, ss.236, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Cilt numarası: 1
  • Basıldığı Şehir: Texas
  • Basıldığı Ülke: Amerika Birleşik Devletleri
  • Sayfa Sayıları: ss.236
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background and Aims Treatment-related acute toxicities remain important causes of morbidity and treatment modification in acute lymphoblastic leukemia (ALL). This study aimed to evaluate the frequency, distribution, and clinical outcomes of non-infectious acute toxicities developing during intensive chemotherapy using internationally accepted standardized classification systems, and to determine independent risk factors associated with toxicity development. Methods A total of 134 patients with ALL, who were treated with BFM-based protocols were retrospectively analyzed. Non-infectious acute toxicities were graded in a standardized manner using both the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and ALL-specific Ponte di Legno (PDL) consensus criteria. Thus, methodological standardization was ensured by applying both the general oncological toxicity classification system and disease-specific consensus definitions. Independent risk factors for high toxicity risk (≥2 different toxicities) were evaluated using multivariate logistic regression analysis. Results At least one non-infectious acute toxicity developed in 87.3% of the patients. The treatment-related mortality rate was 3%. Sixty-seven percent of observed toxicities occurred during the induction phase. The most common toxicities were mucositis (74.6%), hypertension (28.4%), and psychiatric disorders (15.7%). In multivariate analysis, older age at diagnosis was identified as an independent risk factor for increased toxicity risk (p=0.005), whereas being in the standard-risk group was found to be protective (p=0.048). The adolescent age group had a markedly higher risk for thrombosis, metabolic complications, and psychiatric disorders. While body mass index was not associated with overall toxicity burden, it was a significant risk factor for the development of diabetes and hyperlipidemia. The rates of pancreatitis (2.2%), osteonecrosis (0.7%), and sinusoidal obstruction syndrome (2.2%) defined according to PDL criteria were consistent with the literature. Conclusions The burden of non-infectious acute toxicity is high among adolescents and high-risk groups. Early identification of risk factors and follow-up strategies based on standardized toxicity classification are critical for planning personalized supportive treatments and reducing morbidity